OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.55 SEK | -5.07% |
|
+10.51% | +39.39% |
| May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 73.13M | - | |||||
| 78.65B | - | - | ||||
| 8.94B | ||||||
| 5.16B | ||||||
| 4.85B | - | - | ||||
| 4.19B |
- Stock Market
- Equities
- ORX Stock
- Charts Orexo AB
- Sector Chart
